Mediar Therapeutics is a biotechnology company focused on developing treatments for fibrosis. The company aims to halt fibrotic activity by targeting myofibroblasts, the key pathogenic cells in fibrosis that drive scarring, disease progression, and organ failure.

Mediar Therapeutics

Mediar Therapeutics is a biotechnology company pioneering a new approach to fibrosis treatment that halts the disease at a different source – the fibrotic mediators that drive disease progression. 

Mediar was founded based on a deep understanding of the complex science underlying fibrosis onset and progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar is derisking the path forward for fibrosis therapies in clinical development. 

For more information, contact info@mediartx.com

Agent Capital

Mission BioCapital

ONO Pharmaceutical

Pfizer Venture Investments

Mass General Brigham Ventures

Bristol-Myers Squibb

Eli Lilly & Company Foundation

Pureos Bioventures

ShangPharma Innovation

Sofinnova Partners

Novartis Venture Fund

Ono Venture Investment

Gimv

⭐ This Pulmonary Fibrosis Awareness Month, we’re united in the fight against #fibrosis! ⭐ 

At Mediar, we’re committed to developing innovative treatments to combat fibrosis and improve the lives of those affected by this challenging condition. Pulmonary fibrosis affects over 200,000 people in the U.S. alone, causing scarring in the lungs and making it difficult to breathe. We’re proud to support the Pulmonary Fibrosis Foundation in its mission to raise awareness and drive research.

Join us during Pulmonary Fibrosis Awareness Month as we stand with the PF community, share stories, and highlight the urgent need for continued research and support.

#PulmonaryFibrosisAwareness #FightFibrosis #PFF #PFAM

This week, Mediar is at the 8th Annual IPF Summit in our hometown Boston, where our Chief Medical Officer Jeffrey Bornstein, MD and Clinical Advisory Board Member Toby Maher, MD, PhD, Professor of Clinical Medicine & Director of Interstitial Lung Disease at The University of Southern California, will participate in a panel discussion. 

“Innovative Strategies to Mitigate the Competitive & Challenging Nature of Clinical Trials in High-Risk Rare Diseases” will highlight recruiting patients in rare disease populations, digital health technology for remote monitoring, and improving efficacy and efficiency of clinical trials. 

To join us on Tuesday August 20 at 2:30 pm, register here: https://lnkd.in/ezEyYMs

#fibrosis #biotech #IPF2024

This month we celebrate the work anniversaries of three team members who bring dedication, talent, and passion to our organization every day. 🎊 

Chelsea Duncan, Ruoyu Zhuo, and William Feeney, thank you for being an essential part of our journey as we fearlessly chart a different course toward patient impact in the treatment of #fibrosis.  

We appreciate all you do to make our company thrive! 🙌

#TeamAnniversaries #WorkMilestones #EmployeeAppreciation 
#CompanyCulture #biotech

Mediar is thrilled to share we have initiated our second clinical program in our portfolio of novel first-in-class antibodies designed to halt fibrosis and received both orphan drug and fast track designations for MTX-463, our anti-WISP program in a separate Ph-1 study: two pivotal milestones in our pursuit to fulfill the significant gap in #fibrosis treatment.

By targeting the myofibroblast - the key pathogenic cell in fibrosis that drives scarring, disease progression and organ failure - we aim to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach.

Read more here: https://lnkd.in/gM2pqQEy

#Biotech

Today marks a very special milestone at Mediar Therapeutics: Our first employee and CSO leader, Paul Yaworsky, PhD, is celebrating his 5th year! 🎊 

Paul, your scientific acumen, unwavering dedication, and infectious enthusiasm have been paramount to Mediar’s ability to advance a novel fibrosis portfolio into the clinic. 
 
You inspire us to go above and beyond to realize our mission for patient impact in the treatment of #fibrosis.  
 
Here’s to many more years of success! 

#TeamAnniversaries #WorkMilestones #EmployeeAppreciation #CompanyCulture #biotech

Cheers to Timothy Kiprono and Jeffrey Bornstein, MD who are celebrating their anniversaries with Mediar! 

Your passion and expertise have made a remarkable impact on our workplace and our mission to pioneer a new path in #fibrosis treatment. 
 
Looking forward to many years to come!

#CompanyCulture #biotech

Welcome Thendral Selvam, our Summer Co-Op graduate student majoring in biotechnology at Northeastern University. 

Fun fact:  Thendral is a foodie who loves cooking – noting she finds it a relaxing and delicious way to express her creativity – as well as exploring different restaurants and cafes. 

We’re excited to have you on board for an enriching, immersive experience in 
#biotech.

#fibrosis #CompanyCulture

We’re back from our Summer shutdown and energized with some exciting updates!

Congratulations to Gabby Dower, PhD, Aashna Gupta, SHRM-CP, Ben Wilks, PhD, Morgan Fetherolf, PhD and Chelsea Duncan on your recent promotions!

Thank you all for being part of our stellar team!

#fibrosis #CompanyCulture #biotech

Summer is (finally) here, and Mediarites are looking forward to fun in the sun and our week-long summer shutdown. ☀🌴 

It’s time to wind down, relax and rejuvenate with family and friends.

Wishing you a safe and healthy Fourth of July! 

#CompanyCulture #fibrosis #biotech

Big congratulations to Mediarite Morgan Fetherolf, PhD, Senior Scientist, for winning our Q2 Living the Values Award! 🎊 
 
Throughout this past quarter, Morgan has exemplified our core values of curiosity, integrity, and community. He tackles challenges with an infectious smile and unwavering determination. His strong work ethic and genuine concern for those around him are truly inspiring.

Keep on rockin’, Morgan!
 
#CompanyCulture #biotech #fibrosis

MEDI

COM:MEDIARTX

Mediar Therapeutics

locale

market

industry

website

linkedin

founding date

investor of

Metrics